Asterias Biotherapeutics (AST) Reports In-Line Q4 EPS

Asterias Biotherapeutics (NYSE: AST) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $608 thousand versus the consensus estimate of $1.07 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• Sunbelt Rentals Holdings, Inc. (SUNB) Reports Q2 EPS of $1.18